A first-in-human phase I study of the ATP-competitive AKT inhibitor Ipatasertib demonstrates Robust and safe targeting of AKT in patients with solid tumors

1. Saura, C.
2. Roda, D.
3. Roselló, S.
4. Oliveira, M.
5. Macarulla, T.
6. Pérez-Fidalgo, J.A.
7. Morales-Barrera, R.
8. Sanchis-García, J.M.
9. Musib, L.
10. Budha, N.
11. Zhu, J.
12. Nannini, M.
13. Chan, W.Y.
14. Sanabria Bohórquez, S.M.
15. Meng, R.D.
16. Lin, K.
17. Yan, Y.
18. Patel, P.
19. Baselga, J.
20. Tabernero, J.
21. Cervantes, A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1158/2159-8290.CD-16-0512 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus